Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426321 | 0.90 | ALDH1A1 (0.37) | ALDH1A1HPGDKMT2AF2LMNA | |
| SCHEMBL3426951 | 0.86 | HPGD (0.35) | ALDH1A1HPGDKMT2AF2LMNA | |
| SCHEMBL3425741 | 0.83 | ALDH1A1 (0.40) | ALDH1A1HPGDKMT2ALMNAKEAP1 | |
| SCHEMBL13433217 | 0.83 | KMT2A (0.51) | ALDH1A1HPGDKMT2AF2LMNA | |
| SCHEMBL3426725 | 0.80 | ALDH1A1 (0.41) | ALDH1A1HPGDKMT2AF2LMNA | |
| SCHEMBL3426320 | 0.76 | ALDH1A1 (0.37) | ALDH1A1HPGDKMT2AF2LMNA | |
| SCHEMBL13433216 | 0.76 | KMT2A (0.47) | ALDH1A1HPGDKMT2AF2LMNA | |
| SCHEMBL3428092 | 0.74 | ALDH1A1 (0.37) | ALDH1A1HPGDKMT2ALMNAKEAP1 | |
| SCHEMBL3426950 | 0.74 | ALDH1A1 (0.35) | ALDH1A1HPGDKMT2AF2LMNA | |
| Bromide SCHEMBL8469213 | 0.73 | HSP90AA1 (0.48) | ALDH1A1HPGDKMT2AF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7695980-B2 | Chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20060199833-A1 | Novel chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1658495-A1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | Roche Diagnostics GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005015214-A1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199833-A1 | Novel chemiluminescent compounds and their use | LANCL1, LPO, HLCS | ALDH1A1 577/4885HPGD 497/4885KMT2A 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.